What is the current stock price of Contineum Therapeutics, Inc. Class A Common Stock (CTNM)?

As of the latest market data, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is trading at $12.87. The stock has seen a gain of 0.31% today.

Does Contineum Therapeutics, Inc. Class A Common Stock (CTNM) pay a dividend?

Based on current data, Contineum Therapeutics, Inc. Class A Common Stock does not have a confirmed active dividend policy.

What is the market cap of Contineum Therapeutics, Inc. Class A Common Stock?

The current market capitalization of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is approximately unavailable.

CTNM

Contineum Therapeutics, Inc. Class A Common Stock·Healthcare

12.87

0.312%(+0.04)

Market Closed

16.94

31.624%(+4.07)

After Hours

Last Updated: — ET

52W L: $3.3552W H: $16.33

CTNM NEWS

defenseworld.net

Mar 22

Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of “Moderate Buy” from Analysts

Contineum Therapeutics, Inc. (NASDAQ: CTNM - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating

businesswire.com

Mar 13

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on March 12, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common st.

businesswire.com

Mar 5

Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2025 financial results and affirmed its key clinical development milestones. “We're off to a strong start in 2026, having recently dosed the first patient in our global Phase 2 idiopathic pulmonary f.

businesswire.com

Mar 3

Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11th at 2:20 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors sectio.

businesswire.com

Feb 18

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on February 17, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common.

zacks.com

Feb 4

Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year?

Here is how Contineum Therapeutics, Inc. (CTNM) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.

Company Profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2024-04-05

Beta

1.39

Websitewww.contineum-tx.com↗